Meeting polypoidal choroidal vasculopathy treatment needs halfway

Abstract

Polypoidal choroidal vasculopathy (PCV) is a subtype of neovascular age-related macular degeneration (nAMD) that accounts for up to 50% of nAMD cases in Asia. 1 The PCV complex comprises polypoidal lesions (PL) and branching neovascular network (BNN), both of which are found between the retinal pigment epithelium (RPE) and the outer portion of Bruch’s membrane. 2 Hence, PCV should be considered a variant of type 1 neovascularization. 3 In addition, studies of the choroidal background suggest PCV resides within the pachychoroid spectrum of diseases, character-ized by choroidal thickening, dilated Haller’s layer vessels, and attenuation of the overlying choriocapillaris. 4